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Abstract
Transformation of epithelial cells into connective tissue cells (epithelial-mesenchymal transition, EMT) is a complex
mechanism involved in tumor metastasis, and in normal embryogenesis, while type II EMT is mainly associated with
inflammatory events and tissue regenaration. In this study we examined type II EMT at the ultrastructural and molecular
level during the inflammatory process induced by Freund’s adjuvant treatment in rat mesenteric mesothelial cells. We found
that upon the inflammatory stimulus mesothelial cells lost contact with the basal lamina and with each other, and were
transformed into spindle-shaped cells. These morphological changes were accompanied by release of interleukins IL-1alpha,
-1beta and IL-6 and by secretion of transforming growth factor beta (TGF-b) into the peritoneal cavity. Mesothelial cells also
expressed estrogen receptor alpha (ER-a) as shown by immunolabeling at the light and electron microscopical levels, as well
as by quantitative RT-PCR. The mRNA level of ER-a showed an inverse correlation with the secretion of TGF-b. At the cellular
and subcellular levels ER-a was colocalized with the coat protein caveolin-1 and was found in the plasma membrane of
mesothelial cells, in caveolae close to multivesicular bodies (MVBs) or in the membrane of these organelles, suggesting that
ER-a is internalized via caveola-mediated endocytosis during inflammation. We found asymmetric, thickened, electron
dense areas on the limiting membrane of MVBs (MVB plaques) indicating that these sites may serve as platforms for
collecting and organizing regulatory proteins. Our morphological observations and biochemical data can contribute to form
a potential model whereby ER-a and its caveola-mediated endocytosis might play role in TGF-b induced type II EMT in vivo.
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Introduction
Epithelial-mesenchymal transition (EMT) is a biological process
that allows a polarized epithelial cell to undergo several
biochemical/morphological changes to gain a mesenchymal
phenotype [1]. The process was first described by Elisabeth Hay
who also depicted the basic differences of these cellular actions
during embryogenesis and tumorigenesis [2]. Since then three
subtypes of EMTs have been distinguished with different
functional consequences. Besides epithelial-mesenchymal transi-
tion during embryogenesis (type I) and tumorigenesis (type III),
type II EMT is associated with wound healing, tissue regeneration
and organ fibrosis [3], [4]. It has been demonstrated that upon
inflammation many cells (monocytes/macrophages, fibroblasts)
can trigger type II EMT through secretion of growth factors such
as transforming growth factor-beta (TGF-b) or epidermal growth
factor (EGF). Most prominent among these cells are the
macrophages and activated resident fibroblasts that accumulate
at the site of injury and release these growth factors [1], [2], [5].
TGF-b was first described to induce EMT via Smad 2/3-
dependent pathway and meanwhile it became evident that the
cellular actions of the cytokine can be modulated and defined by
other Smad-independent signaling pathways like the MAP kinase
pathways [6]–[8].
Recently, estrogen receptor alpha (ER-a) has been suggested as
another player in the molecular mechanism of EMT [9]–[11]. For
long, estrogen receptors (ER-a, ER-b) have been considered
exclusively as transcription factors acting inside the nucleus [12],
[13]. However, the discovery of its membrane-associated form and
the ER–mediated transcription in the absence of its ligand
generally changed this concept [14], [15]. The theory of a
hormon-independent ER-a activation that can serve as a
mechanism to amplify growth factor pathways [16] has also been
accepted by now. It has been proved that a small percentage of
ERs (5–10%) reside in the cell membrane and can elicit both
genomic and non-genomic responses by activating multiple
protein kinase cascades that include MAPK, protein kinase C,
Src kinase and PI3K [17]–[23].
ER-a and TGF-b have opposing roles in cell proliferation and
differentiation of epithelial cells. Their regulatory pathways
intersect and ER-a blocks the TGF-b pathway at different cellular
levels inside the nucleus as well as in the cytoplasm and plasma
membrane. Both transcription factors have a prominent role in
maintaining a controlled signaling that is essential for cell and
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tissue homeostasis and both act in a cell-specific and context-
dependent manner [24]–[25].
In our previously published papers we showed that mesothelial
cells that form a continuous squamous epithelial layer on the two
sides of the mesentery undergo epithelial-mesenchymal transition
(EMT) upon Freund’s adjuvant treatment [26]. It has also been
proved that upon inflammatory stimuli mesothelial cells can
assume a macrophage character demonstrated by the expression
of the macrophage marker, ED1 [27] and they can serve as a
source of activated macrophages during inflammatory events [28].
Besides this finding, it is also known that macrophages express ER-
a [29], [30]. These data together led us to examine whether
mesothelial cells express ER-a and if so, what is the subcellular
distribution of the receptor. We examined the morphological and
biochemical changes of mesothelial cells under inflammatory
stimuli in vivo. This study reports for the first time that ER-a is
expressed by the rat mesenteric mesothelial cells and an inverse
correlation between the level of ER-a expression and the
peritoneal secretion of TGF-b can be observed in response to
Freund’s adjuvant treatment. The present results show that ER-a
is associated with caveolin-1 protein and the receptor is
presumably internalized via caveola-mediated endocytosis. Our
morphological observations and biochemical data together indi-
cate that ER-a and its caveola-mediated endocytosis may play role
in TGF-b induced type II epithelial-mesenchymal transition.
Materials and Methods
Ethics Statement
All rat experiments were carried out in accordance with the
recommendations in the Guide for the use of Adjuvants in
Research of the National Institutes of Health and approved by the
Institutional Animal Care and Use Committee of the University of
Massachusetts Amherst [31] and Semmelweis University’s Insti-
tutional Animal Care and Use Comittee. All efforts were made to
minimize suffering.
Material and Treatment
Rat mesentery (peritoneum of small intestine) was isolated from
control and Freund’s adjuvant (Sigma, Steinheim, Germany)
treated Sprague-Dawley male and female rats (200–400 g). 1 ml
complete Freund’s adjuvant was injected into the peritoneal cavity.
One day (D1), 2 days (D2), 3 days (D3) and 5 days (D5) following
intraperitoneal injections the animals were sacrificed by decapi-
tation and mesentery samples were removed.
Collection of peritoneal fluid, isolation of mesothelial
cells
To determine the secretion level of TGF-b, peritoneal fluid (PF)
samples were collected from both male and female animals by
washing the peritoneal cavity with 2 ml phosphate-buffered saline
(PBS). The PF samples were centrifuged with 1000 rpm, for
10 min at 4uC and the supernatants were stored at 220uC until
use for immunoblotting.
For isolating mesothelial cells, mesentery was removed and
placed into 0,2% collagenase diluted DMEM tissue culture
medium (Sigma) for 45–50 minutes at 37uC. The solid remnants
(adipose tissue, connective tissue) were removed and samples were
washed three times in PBS and centrifuged with 1000 rpm, for
10 min at room temperature. The pellets were then placed in
liquid nitrogen for 10 minutes and stored at 280uC until RNA
isolation for quantitative RT-PCR.
RNA isolation and quantitative RT-PCR
Total RNA was extracted with RNeasy tissue mini kit
(QIAGEN Inc., Chatsworth, CA). For qualitative and quantitative
analysis of RNA preparations, RNA 6000 Nano Chip kits in an
Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara,
CA) was used according to the manufacturer’s instructions.
Following RNA isolation, RNAs obtained were transcribed into
cDNAs using SuperScriptTM III First-Strand Synthesis SuperMix
(Life Technologies, Carlsbad, CA), according to the manufactur-
er’s instructions. From each samples, 0.5–1 mg of total RNA was
converted into cDNA. Real-time PCR was performed using
Taqman Universal Master Mix II, No UNG and the 7900HT
Real-Time PCR System (Life Technologies, Carlsbad, CA), with
the following parameters: 50uC for 2 min and 95uC for 10 min,
followed by 40 two-step cycles at 95uC and at 60uC for 1 min.
Applied Biosystems pre-designed TaqManH Gene Expression
Assays were used for real-time PCR (Il6 Rn00561420_m1, Il1a
Rn00566700_m1, Il1b Rn00580432_m1, Esr1 Rn00664737_m1,
GAPD.4352338E, Esr2 Rn00562610_m1, Gpr30
Rn00592091_s1 and B2m Rn00560865_m1). The qRT-PCRs
were executed in triplicate using TaqMan probe synthesized by
Applied Biosystems). SDS 2.3 (Applied Biosystems, Foster City,
CA) and RQ manager 1.2 softwares (Applied Biosystems, Foster
City, CA) were applied for calculation of the threshold cycle (Ct)
values in each sample.
Expression level was calculated by the ddCt method, and fold
changes (FC) were obtained using the formula 2-ddCt. Computed
internal control corresponding to the geometric mean of Ct values
of the two houskeeping genes (GAPD and B2m) was used for the
ddCt calculation. Gene expression levels at different time points
were compared to controls using ANOVA and t-test with a
statistical software SPSS version 13 (SPSS Inc., Chicago, IL,
USA).
Antibodies
Primary antibodies were polyclonal anti-caveolin-1 antibody
(1:40 for IEM, Transduction Laboratories) and polyclonal anti
estrogen-receptor alpha antibody (H-184): sc-7207 (1:50-IEM,
Santa Cruz Biotechnology, Inc). Biotinylated anti-rabbit IgG
(1:200) was used as a secondary antibody (VECTOR Laboratories
Inc, Burlington, Canada). For confocal microscopy, streptavidin
Alexa Fluor 488 conjugate and streptavidin Alexa Fluor 555
conjugate (MolecularProbes, Leiden, the Netherlands) were used
(1:200). The nuclei were stained with DAPI (Vectashield DAPI
mounting medium, Burlingame, Canada). For immunogold
labeling Protein A conjugated to 10- (1: 80) and 15-nm (1:60)
gold particles was manufactured and kindly gifted by the Cell
Microscopy Centre, Utrecht, The Netherlands.
Western blotting
The protein contents of the supernatants from peritoneal fluid
samples were determined by the Bradford method [32] and
diluted to a concentration of 1 mg/ml. Afterwards the samples
were solubilized with reducing Tris-SDS buffer (Tris 0.5 M
pH 6.8, 10% glycerol, 2% SDS, 0.00125% bromophenol blue,
0.5% mercapto-ethanol) and heated at 95uC for 4 min. 15 ml per
well from the samples were loaded onto an 10% Acrylamide/Bis
gel and separated by electrophoresis. After separation, proteins
were transferred onto a nitrocellulose membrane (Amersham, GE
Healthcare Biosciences, Pittsburgh) in a buffer containing Tris–
Glycine pH 8.3, 0.1% SDS and 20% methanol.
Aspecific reactions were blocked at room temperature for 2 h in
PBS-Tween (0.5 M PBS, Tween 0.05%) containing 5% skim milk
powder. The membranes were then incubated with polyclonal
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anti-rabbit TGF-b primary antibody (Cell Signaling Technology
Inc., Beverly, MA) diluted 1:1000 at 4uC for overnight. After
washing in PBS-Tween the membranes were treated with species-
specific peroxydase-conjugated secondary antibody (Amersham,
GE Healthcare Biosciences, Pittsburgh) for 1 h at room temper-
ature. The labeled protein bands were visualized by the ECL Plus
chemiluminescence method and developed onto high performance
chemiluminescence film (Amersham, GE Healthcare Biosciences,
Pittsburgh). Relative optical densities were measured using the
ImageJ software (U. S. National Institutes of Health, Bethesda,
Maryland) and the results of four independent experiments were
compared and statistically analyzed. The significance was tested by
the ANOVA method and Tukey’s HSD test.
Tissue fixation for light and electron microscopy
Mesentery was isolated from both control and Freund’s
adjuvant-treated animals. The samples were fixed either in a 1:1
mixture of 2% glutaraldehyde (GA in 0.2 M cacodylate buffer)
and 2% OsO4 in distilled water (30 min, on ice) or freshly
prepared 4% paraformaldehyde (PFA) in 0.1 M PB (2–4 h, room
temperature). The samples were washed in cacodylate buffer and
PBS, respectively and the adipose tissue was removed from the
mesentery. The GA-Os fixed material was proceeded to electron
microscopic embedding, while the PFA-fixed samples were used
for immunocytochemistry.
Electron Microscopy
The GA-Os fixed samples were washed in 0.1 M cacodylate
buffer three times, dehydrated with ethanol and stained with 1%
uranyl acetate (in 70% ethanol for 1 h, room temperature) prior to
araldite embedding. Ultrathin sections were contrasted with
uranilacetate and lead citrate. The samples were analyzed in a
Hitachi H-7600 (Tokyo, Japan) transmission electron microscope.
Preparation of semithin and ultrathin cryosections
The PFA-fixed samples were stored in 1% formaldehyde (in
0.1 M PB) at 4uC until further processing. For semithin
cryosectioning and immunolabeling, the fixed samples were
washed twice in PBS, once in 0.02 M glycin/PBS and infiltrated
gradually with gelatine solutions of increasing concentrations (2%–
5%–12% in PB) at 37uC for 30 min each. The samples were
oriented in liquid gelatin and cut into small blocks. For
cryoprotection, the blocks were infiltrated with 2.3 M sucrose at
4uC overnight and afterwards mounted on metal pins, frozen and
stored in liquid nitrogen. For preparing semithin and ultrathin
cryosections we used Leica Ultracut S ultramicrotome equipped
with cryo-attachment (Vienna/Austria). The pickup solution was a
1:1 mixture of 2.3 M sucrose and 1.8% methylcellulose.
Immunolabeling for light and electron microscopy
0.5 mm semithin sections mounted on microscopic slides were
incubated with 0.02 M glycine in PBS for 15 min and then they
were blocked in PBS containing 1% BSA. Primary antibodies were
applied in 1% BSA containing buffer in a humidified chamber at
4uC (overnight). Polyclonal anti-caveolin-1 and polyclonal anti
estrogen-receptor alpha antibodies were used at the dilution 1:200
and 1:100, respectively. After washing with PBS, this was followed
by a 1 h incubation with the secondary antibody in a humidified
chamber at room temperature. Sections were then rinsed with
PBS, stained with DAPI, placed under coverslips and visualized in
a Bio-Rad (Ontario, Canada) Radiance 2100 Rainbow confocal
microscope.
For cryosectioning and immuno-EM, the fixed tissues were
further processed as described [33]. Ultrathin cryosections
prepared at 2100uC were transferred to copper grids by pickup
with a 1:1 mixture of 2.3 M sucrose in PBS and 1.8%
methylcellulose. For immunogold labeling, the grids were incu-
bated first on 2% gelatin/PBS at 37uC, blocked with 0.02 M
glycine/PBS and subsequently incubated with primary antibodies
followed by protein A-gold. The sections were contrast stained
with 2% uranyl acetate/oxalate, pH 7, followed by 0.4% uranyl
acetate pH 4 and 1.8% methyl cellulose and dried. The
cryosections were analyzed in a Hitachi H-7600 (Tokyo, Japan)
transmission electron microscope at 80 kV.
Results
Ultrastructural and biochemical evidences of type II EMT
in mesothelial cells in vivo
In untreated, control animals mesothelial cells form a contin-
uous simple squamous epithelial layer on both sides of the
mesentery. As observed in the electron microscope, the cytoplasm
of these cells was rather poor in cell organelles and the cells were
dominated by the nucleus. A continuous basal membrane
separates the mesothelial cell layer from the underlying connective
tissue and maintains the integrity of the mesothelial layer.
Caveolae (caveolin-containing lipid rafts seen as flask-shaped
invaginations of the cell membrane) were abundantly present on
the basolateral and apical surfaces of the cells (Fig. 1A).
Our previous light microscopical data revealed that mesothelial
cells lose their epithelial character (decreased cytokeratin, E-
cadherin expression) upon Freund’s adjuvant treatment and
obtain a mesenchymal phenotype by expressing vimentin [26].
The inflammatory stimuli changed remarkably the ultrastructure
of mesothelial cells as well. These changes culminated on the
second to third day (D2/D3) after treatment. From the fifth day
(D5) on the tissue started to recover and the repairment was
morphologically accomplished by the eleventh day (D11). Char-
acteristic changes were the disintegration of basal membrane and
transformation of the squamous mesothelial cells into individual
cuboidal-shaped cells in two days after treatment (Fig. 1B). By the
fifth day, cells developed numerous lamellar processes and became
spindle-shaped (Fig. 1C). The cytoplasmic compartments were
more prominent: an increased number of mitochondria, polyri-
bosomes, numerous vesicles and a growing number of multivesic-
ular bodies (MVBs) could be observed in parallel with the
inflammatory events of the surrounding tissue. A striking
observation was the presence of thickened, electron-dense domains
on the limiting membrane of MVBs with a fine coat of medium
electron density on the cytosolic side (Fig. 1D). These specific
membrane domains (referred from now on as MVB plaques)
disappeared by the later stages of the MVB maturation process
and could not be observed in the membrane of intermediate forms
between MVB and lysosome (Fig. 1E).
In addition to ultrastructural changes, it was of primary
importance to see if Freund’s adjuvant treatment induces
inflammatory responses in our in vivo system at a molecular level
as well. To verify this, we determined the expression levels of pro-
inflammatory cytokines in mesothelial cells as they are well-known
to be involved in immune responses and inflammatory processes.
The results of quantitative RT-PCR showed that mRNA
expression levels of interleukin type 1alpha and type 1beta and
also interleukin 6 increased in mesothelial cells by Freund’s
adjuvant treatment (Fig. 2A). The elevated mRNA levels of these
cytokines correlated with the time-scale of the observed morpho-
logical changes during the inflammatory events: expression levels
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of mRNAs had a peak on D3 followed by a significant
downregulation that could be observed from the fifth day
indicating the termination of the inflammatory response. Our
Western blot data showed that TGF-b was secreted into the
peritoneal cavity (Fig. 2B, C) and the secretion of the cytokine was
in accordance with the morphological changes and with the
Figure 1. Fine structural aspects of EMT in mesothelial cells upon Freund’s adjuvant treatment. (A) Non-treated (control) cells are flat
and form a continuous layer on the basal lamina (arrowheads). Caveolae are abundantly present in the control cells seen as small flask shape
invaginations of the plasma membrane. (B) Upon inflammation mesothelial cells progressively lose the connection with the underlying connective
tissue as the basal lamina becomes discontinuous and disintegrates. The cytoplasm of mesothelial cells contains lipid droplets (L) that are probably
identical with internalized Freund’s adjuvant oil droplets. (C) On the fifth day of treatment, mesothelial cells assume a spindle-shape morphology with
several villar or lamellar processes (arrowheads) on their surface. (D) An increasing number of multivesicular bodies (MVB) appear from D3. Note
specific membrane domains of the organelles (arrowheads) showing an increased density and apposition of a coat on the cytosolic side (MVB
plaques). (E) The MVB plaques disappear by the later stages of MVB maturation, by D5. Scale bars: (A) 1 mm (B) 2 mm (C) 2.9 mm (D) 500 nm, (E) 1 mm.
doi:10.1371/journal.pone.0079508.g001
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expression levels of inflammatory cytokines indicating its role in
EMT.
Estrogen receptor alpha (ER-a) is expressed in
mesothelial cells
Since mesothelial cells can serve as one of the sources of
activated macrophages upon Freund’s adjuvant treatment and it is
known that macrophages express ER-a, the question arose
whether mesenteric mesothelial cells also express the molecule?
Our present results show that ER-a is present in mesothelial cells
both under steady state and inflammatory conditions. As control
cells were flat and the cytoplasm formed a thin rim around the
nucleus, it was difficult to define the exact nuclear, cytoplasmic or
plasma membrane (PM) localization of the marker with light
microscope (Fig. 3A). The morphological changes of the cells upon
inflammation enabled us to better detect the localization of ER-a.
Confocal microscopical results after immunofluorescence detec-
tion of ER-a showed that labeling appeared in the nucleus,
cytoplasm as well as in the plasma membrane and on the
consecutive days after treatment the intensity of the labeling
increased (Fig. 3B–D). In those mesothelial cells that had entirely
lost the connection with the basal lamina, significant ER-a labeling
was found on the plasma membrane and this distribution was
clearly apparent on D5 samples (Fig. 3D). Distribution of labeling
along the PM had been changed during the inflammatory process:
while in control samples the labeling showed a continuous line at
the PM (Fig. 3A), it clustered at certain areas of the plasma
membrane in treated cells.
Since we found no detectable differences in ER-a labeling
between female and male animals, we further carried out our
experiments with samples taken from male rats if not indicated
otherwise.
To further clarify the presence of ER-a in mesothelial cells we
measured its expression at the mRNA level by quantitative RT-
PCR. Our results revealed that control mesothelial cells expressed
ER-a mRNA and it showed a significant downregulation during
the progression of the inflammatory process (Fig. 3E). (We found
the same pattern of changes in the mRNA expression levels of ER-
b and G protein-coupled receptor 30, GPR30 as well (Fig. S1.).)
Estrogen receptor alpha associates with caveolin-1 both
in non-treated and treated mesothelial cells
Since there are controversial data in the literature on the
subcellular localization of ER-a in various cell types, we carried
out double immunolabeling to detect the fine localization of ER-a
as well as their possible co-localization with the coat protein
caveolin-1. Our confocal microscopical results show that under
inflammatory conditions ER-a colocalized with caveolin-1 both
inside the cytoplasm and in the PM (Fig. 4). There were no
differences in the distribution of the two markers between D3 and
D5 (data not shown). However, in those mesothelial cells that were
partially attached to the basal membrane, there was a remarkable
colocalization of ER-a and caveolin-1 on the luminal surface of
the cells (Fig. 4A). In contrast, with the disintegration of the basal
membrane from the third day, ER-a appeared all over the plasma
membrane in caveolin-positive membrane domains and colocali-
zation could be detected also inside the cytoplasm (Fig. 4B). To
obtain a more precise view on the localization of ER-a at the
ultrastructural level, we carried out immunocytochemistry on
ultrathin frozen sections of both non-treated and treated cells.
Consistent with the immunofluorescence data, the same distribu-
tion of ER-a and caveolin-1 could be found on double-labeled
ultrathin frozen sections of treated cells. The immunoelectron
microscopic results clearly showed that at the peak time of
inflammation (D3 and D5) ER-a occurred not only at the plasma
membrane but appeared also inside the cytoplasm (Fig. 5A, B).
Here ER-a (together with caveolin-1) was localized in forming or
mature MVBs either in their limiting membrane, in association
with caveolin-1 or in caveolae, in close vicinity of MVBs (Fig. 5A,
B). In untreated, control mesothelial cells ER-a labeling was
accumulated along the plasma membrane on both the luminal and
basolateral sides of the cells, preferentially in caveolin-positive
vesicles, caveolae (Fig. 5C). ER-a labeling was also observed inside
the nuclei of both untreated and treated mesothelial cells, but to a
lesser extent.
Discussion
Epithelial-mesenchymal transition (EMT) is a complex mech-
anism that is characterized by a series of events including loss of
cell-cell junctions and cell-matrix adhesion, reorganization of
cytoskeleton resulting in loss of apical-basolateral polarity and
assuming a mesenchymal chararacter such as spindle-shape
morphology and motility. Due to its role in tumor metastasis as
well as in normal embryogenesis and wound healing, the EMT is
currently under intensive investigations [1]–[5].
In a previous paper we have shown that rat mesenteric
mesothelial cells undergo EMT upon inflammatory stimuli
induced by Freund’s adjuvant treatment [26]. In the present
paper we furnish additional evidence for the inflammatory
response of the tissue by showing that the morphological changes
at the ultrastructural level were in correlation with the expression
levels of pro-inflammatory cytokines (IL 1a, 1b and IL-6)
measured in mesothelial cells. This finding further supports the
theory that mesothelial cells may contribute to the amplification of
inflammatory responses by secreting interleukines and in this way,
they are able to play an active role in peritoneal inflammatory
events [34]–[36]. Proinflammatory cytokines (TNFa, IL1, IL6) are
well known to induce immune and inflammatory responses by
binding to their receptors. The major source of proinflammatory
cytokines is the macrophages that produce plethora of these
molecules including TNFa, IL-1, IL-6, Il-12, IL-15 and IL-18
[37]. Macrophages also secrete TGF-b at the site of injury that has
a role in inducing EMT [1], [2], [5]. TGF-b is an important
morphogenic factor initiating and maintaining EMT via different
signaling routes (Smad-dependent, Smad-independent). Smad-
independent signaling pathways including the activation of Erk,
JNK, p38 MAP kinase cascades are considered to help and
complete the process of TGF-b induced EMT. Although there are
limited data about the exact mechanisms and biological conse-
quences of these accessory signaling routes, it is apparent that
TGF-b induced canonical and non-canonical pathways intersect
and both are essential for effective signaling [38]–[41]. Similarly,
we found significant elevation in the secreted TGF-b concentra-
Figure 2. Expression levels of proinflammatory cytokines in mesothelial cells and peritoneal secretion of TGF-b in response to
Freund’s adjuvant treatment. (A) mRNA expression levels of IL-1alpha (IL1a), IL-1beta (IL1b) and IL-6 increase significantly until the third day
where expression reaches a maximum, then declines to a similar level measured at the beginning of inflammation induction. (B) TGF-b in the
peritoneal cavity follows the same pattern. Western blot using Pan-TGF-b antibody, 46 kDa. M: male F: female. (C) Relative levels of secreted TGF-b
measured by densitometry. The asterisks show significant differences from the control group (p,0,05).
doi:10.1371/journal.pone.0079508.g002
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tion as the inflammation progressed indicating its main role to
organize the EMT upon treatment in our in vivo system as well.
Earlier results from our laboratory have shown that upon
adjuvant stimulation mesothelial cells are detached from the basal
lamina and assume a macrophage character expressing ED1, a
macrophage marker [27] and they can serve as a source of
activated macrophages during inflammatory events [28]. Since
macrophages are known to express ER-a [29], [30], the question
arose whether treated and untreated mesothelial cells do produce
ER-a as well? Our present morphological (confocal and immuno-
EM) and biochemical (qRT-PCR) results show that ER-a is really
Figure 3. ER-a immunolabeling on control and Freund’s
adjuvant-treated mesothelial cells. Confocal micrographs of
semithin frozen sections (A) Mesothelial cells are present on both
sides of the connective tissue (white arrowheads). The labeling lines out
the contour of mesothelial cells and can be detected in the wall of
blood vessels (V) as well. (B–D) Parallel with the rounding up of
mesothelial cells the distribution of ER-a becomes better detectable:
labeling can be observed in the nucleus, cytoplasm as well as on the
plasma membrane both on the second (B) and third (C) days after
treatment.(D) By the fifth day, many of the mesothelial cells express ER-
a mostly along the plasma membrane observable as small punctate
structures. The connective tissue contains different cell types among
which granulocytes express ER-a extensively (white arrow). Nuclei are
stained with DAPI (blue). Scale bars: 10 mm. (E) ER-a mRNA level
measured in mesothelial cells is significantly downregulated in response
to treatment compared to control group. (asterisks: p,0,05).
doi:10.1371/journal.pone.0079508.g003
Figure 4. ER-a associates with caveolin-1 and its distribution
changes upon inflammatory stimuli. Semithin frozen sections
labeled with antibodies against ER-a (green) and caveolin-1 (red).
Strong colocalization (orange) can be observed. (A) Two days after
treatment, mesothelial cells (still attached to the basal lamina) show
abundant expression of ER-a which is colocalized with caveolin-1 inside
the cytoplasm and on the luminal side (arrowheads) of the cells. Less
immunolabeled structures are present on the opposite side of the cell
(arrow). (B) In the consecutive day (D3) when cells become apolar and
lose contact with the basal lamina, a more intensive co-labeling can be
observed over the plasma membrane as well as inside the cytoplasm
with no asymmetric distribution. Nuclei are stained with DAPI (blue)
Scale bars: 10 mm.
doi:10.1371/journal.pone.0079508.g004
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present in treated as well as in control mesothelial cells. This
finding is of special interest since recently it was shown that in
addition to its well known genomic role as a transcription factor,
ER-a has several non-genomic functions. Nowadays it became
generally accepted that a certain amount of ER-a resides in the
plasma membrane and is thought to be responsible for inducing
both genomic and non-genomic actions by activating different
cascades, like PKC, Src kinase, MAPK and PI3K [17]–[23]. Our
present light microscopic data showed that in parallel with the
inflammatory events the labeling intensity of ER-a was signifi-
cantly increased and could be detected in the cytoplasm, plasma
membrane as well as in the nucleus. Besides the novel finding that
ER-a is expressed in mesenteric mesothelial cells, the nuclear pool
of the receptor was less pronounced and unchanged during the
inflammatory events. This directed our focus to study further the
cytoplasmic/plasma membrane pool of ER-a. In mesothelial cells,
still in contact with the basal lamina, the distribution of plasma
membrane ER-a pool showed a certain polarity with a predom-
inant localization on the luminal side, while after being detached
ER-a was distributed all over the plasma membrane. This
redistribution of ER-a in the plasma membrane indicates loss of
cell polarity and is a further proof for the transformation of a
polarized epithelial cell into a non-polarized mesenchymal cell.
An interesting finding in our study was that the mRNA level of
ER-a showed an inverse correlation with the labeling intensity of
the protein on our immunocytochemical specimens demonstrating
that on a transcriptional level ER-a was downregulated. Several
studies have already described that mRNA and protein levels do
not always correlate. The exact mechanism is still unclear, a
possible explanation for this phenomenon can be a protein-protein
interaction, the altered turnover of the molecule and posttran-
scriptional regulation by microRNAs [42]–[49].
A further finding in this study is that both plasma membrane
ER-a and the cytosolic receptor pool were predominantly
associated with caveolin-1 protein. Similar findings are known
from literature showing that ER-a resides in caveolin positive raft
compartments of the plasma membrane in many cells [14], [50].
Caveolin-1 is the major protein component of special highly
hydrophobic membrane domains, called caveolae. Caveolae are
omega-shaped, small plasma membrane invaginations that are
found in most mammalian cell types. They play important role in
many cellular functions including vesicular transport, endocytosis,
transcytosis and are also described to be involved in different signal
transduction events [51]–[55]. Collectively these data suggest that
caveolae are platforms of plasma membrane where, besides other
transduction proteins, ER-a is also present. The fine structural
distribution of the receptor demonstrated by our immuno-electron
micrographs suggests that plasma membrane ER-a is internalized
upon inflammatory stimuli and is targeted to the classical
endosomal pathway: towards cytoplasmic organelles, multivesicu-
lar bodies. This finding is not unusual, since endocytosis of
membrane receptors and their transport along the endosomal
pathway have been described in other signaling systems as well
[56], [57]. Since caveolae are often considered as ‘signaling
platforms’ [58], [59], caveola-mediated endocytosis results in a)
removing signaling molecules (ERalpha, src) from the cell surface
b) providing pathway for biologically important signal transducers
to reach the proper cytoplasmic platforms (late endosomes, MVBs)
where the microenvironment is optimal for their interaction.
Considering the colocalization of ER-a with cavolin-1, it is likely
that internalization is caveola-mediated. This suggestion is further
supported by Christensen et al. showing that inhibition of Cav-1
by siRNA reduced membrane estrogen-receptor a levels [60]. Our
further observation was that by D6 the plasma membrane of
mesothelial cells devoids both clathrin-coated vesicles and caveolae
(Fig. S2) indicating that internalization of signaling molecules (ER-
a, Src-data not shown) in caveolae is presumably important in the
process of EMT.
Figure 5. Electron microscopic immunolabeling on ultrathin
frozen sections to show ER-a distribution in caveolin-positive
lipid rafts and/or caveolae. ER-a was labeled with 15-nm gold
particles and caveolin-1 with 10-nm gold. (A) ER-a can be found both in
the plasma membrane (PM) associated with caveolin-1 (arrows) and (B)
deeper inside the cytoplasm (arrow) in caveolae upon inflammation.
There were no significant differences in the distribution of ER-a
between D3 (A) and D5 (B). (A, B) During multivesicular body (MVB)
formation, ER-a was found in the limiting membrane of these
organelles and in caveolae in their close environment (arrowheads).
(C) In non-treated cells ER-a occured in caveolin positive omega-shaped
invaginations of the PM. This pattern of the markers was detectable
both on the luminal and the basolateral surfaces (arrowheads) in
control mesothelial cells. The bars represent (A) 250 nm, (B) 400 nm (C)
333 nm, insert 250 nm.
doi:10.1371/journal.pone.0079508.g005
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It is known that the association of caveolin and ER-a can
activate MAP kinase pathways by interacting either with the
signaling proteins or with each other [61]–[62]. The best studied
interaction in raft domains of the plasma membrane is the
induction of Erk pathway through Src/Shc/Grb2/Sos protein
complex formation where these proteins physically interact with
both caveolin-1 and ER-a and are activated after TGF-b stimulus
[64],[65]. Taking into consideration these data, we suppose that
ER-a might have a role in our system by modifying the activity of
main signaling pathways via maintaining physical interaction with
signaling proteins such as caveolin-1 and Src (data not shown).
There are limited data available about the localization of the
elements of MAPK cascades inside the cytoplasm. The Erk
pathway is well characterized and these studies illustrate the role of
endosomal compartments. Either the upstream elements of these
non-canonical pathways are described to occur in the plasma
membrane/membrane of early endosomes or the downstream
signaling elements are bound to late endosome/MVB membranes
via different adaptor proteins [66]–[68]. One of these adaptor
proteins (p18) has already been proved to associate with cavolin -1
indicating that upon internalization, the lipid compound of
caveolae - that partially form the limiting membrane of these
endosomal compartments- have importance [69]. They presum-
ably maintain a physical platform to bind the elements of signaling
proteins and in this way, they can orchestrate the spatial and
temporal regulation of different signaling routes. In this paper we
showed that ER-a was found either in the limiting membrane of
MVBs colocalizing with caveolin-1 or in caveolae in close vicinity
to late endosomal/MVB compartments. Comparing the distribu-
tion of the receptor and our EM images showing the MVB
plaques, we hypothesize that the membrane of endosomal
compartments/MVBs can form platforms for molecular clusters
and can organize spatial and temporal distribution of signaling
proteins. Although our results do not prove directly whether PM
ER-a induces signaling from the plasma membrane and whether it
controls accessory pathways, however, its association with
caveolin-1 and Src (data not shown) strongly suggest that it might
play a role in signaling events.
Recent investigations also revealed that ER-a can enhance the
degradation of Smad proteins inside the nucleus via ubiquitin-
proteasome system and inhibit TGF-b signaling [24]. These data
illustrate the role of ER-a as a non-genomic nuclear modifier of
TGF-b signaling cascade.
The main aim of this study was to bring into focus the role of in
vivo cell populations that can help examine the biological processes
of EMT. Our work also draws attention to the role of cellular
compartmentalization (caveolae and endosomes/MVBs) that can
maintain platforms for possible interactions of regulatory proteins
and spatially-temporally might orchestrate the signaling events.
Our morphological observations and biochemical data can
contribute to form a potential model whereby possible ERa-
TGFb cross-talk can further be investigated in vivo. However fine
details of the mechanisms and further functional evaluations are
essential to clarify the exact role of ER-a in mesothelial cells under
inflammatory conditions.
Supporting Information
Figure S1 The changes of mRNA expression levels of
ER-b and GPR30 upon inflammatory stimuli. Similarly to
ER-a, the mRNA levels of ER-b and G protein-coupled receptor
30, GPR30 showed a significant downregulation upon treatment
compared to control group. (asterisks: p,0,05).
(TIF)
Figure S2 Electron micrograph of a mesothelial cell six
days after treatment. The plasma membrane of mesothelial
cells devoid both clathrin-coated vesicles and caveolae six days
after inducing inflammation. Observe the ‘emptiness’ of the cell
surface of the mesothelial cell. N: nucleus. Bar represents 833 nm.
(TIF)
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